PMID- 32169731
OWN - NLM
STAT- MEDLINE
DCOM- 20210719
LR  - 20210719
IS  - 1522-9653 (Electronic)
IS  - 1063-4584 (Linking)
VI  - 28
IP  - 6
DP  - 2020 Jun
TI  - Efficacy and safety of duloxetine in osteoarthritis or chronic low back pain: a 
      Systematic review and meta-analysis.
PG  - 721-734
LID - S1063-4584(20)30915-8 [pii]
LID - 10.1016/j.joca.2020.03.001 [doi]
AB  - OBJECTIVE: To evaluate the efficacy and safety of duloxetine in the treatment of 
      patients with osteoarthritis (OA) or chronic low back pain (CLBP). METHODS: 
      Relevant randomized controlled trials (RCTs) were searched in PubMed, Embase, Web 
      of Science, Cochrane Central Register of Controlled Trials, and 
      ClinicalTrials.gov. Included RCTs compared the efficacy and safety of duloxetine 
      vs placebo in the treatment of OA or CLBP. Weighted mean difference (WMD) were 
      calculated for continuous outcomes while risk ratio (RR) were calculated for 
      dichotomous outcomes. RESULTS: Nine RCTs were included in our meta-analysis. 
      Duloxetine had significant improvement over placebo in Brief Pain Inventory 24-h 
      average pain [WMD: -0.67; 95% confidence interval (CI):-0.80, -0.53], weekly mean 
      of the 24-h average pain (WMD: -0.65; 95% CI: -0.79, -0.52), Patient's Global 
      Impression of Improvement (WMD: -0.41; 95% CI: -0.49, -0.32), Clinical Global 
      Impression of Severity (WMD: -0.32; 95% CI: -0.38, -0.25), European Quality of 
      Life Questionnaire-5 Dimension (WMD: 0.04; 95% CI: 0.02, 0.07). In addition, 
      duloxetine is associated with more treatment-emergent adverse events (TEAEs) (RR: 
      1.25; 95% CI: 1.17, 1.33) and discontinuations for adverse events (AEs) (RR: 
      2.31; 95% CI: 1.81, 2.94). However, there was no statistically significant 
      difference in serious AEs between duloxetine and placebo. CONCLUSION: Duloxetine 
      had modest to moderate effects on pain relief, function improvement, mood 
      regulation and improvement in quality of life with mild AEs in the treatment of 
      OA or CLBP. Future RCTs should focus on comparing duloxetine with other oral 
      drugs and assessing the long-term safety of duloxetine.
CI  - Copyright (c) 2020. Published by Elsevier Ltd.
FAU - Weng, C
AU  - Weng C
AD  - Department of Rheumatology and Immunology, The Second Affiliated Hospital of 
      Soochow University, Suzhou, China. Electronic address: wengchenghua@126.com.
FAU - Xu, J
AU  - Xu J
AD  - Department of Rheumatology and Immunology, The Second Affiliated Hospital of 
      Soochow University, Suzhou, China. Electronic address: medicalxujj@163.com.
FAU - Wang, Q
AU  - Wang Q
AD  - Department of Rheumatology and Immunology, The Second Affiliated Hospital of 
      Soochow University, Suzhou, China. Electronic address: 
      20195233013@stu.suda.edu.cn.
FAU - Lu, W
AU  - Lu W
AD  - Department of Rheumatology and Immunology, The Second Affiliated Hospital of 
      Soochow University, Suzhou, China. Electronic address: 
      20195233016@stu.suda.edu.cn.
FAU - Liu, Z
AU  - Liu Z
AD  - Department of Rheumatology and Immunology, The Second Affiliated Hospital of 
      Soochow University, Suzhou, China. Electronic address: lzchun5190@sina.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20200310
PL  - England
TA  - Osteoarthritis Cartilage
JT  - Osteoarthritis and cartilage
JID - 9305697
RN  - 0 (Analgesics)
RN  - 9044SC542W (Duloxetine Hydrochloride)
SB  - IM
CIN - Osteoarthritis Cartilage. 2020 Sep;28(9):1298-1299. PMID: 32446939
CIN - Osteoarthritis Cartilage. 2021 May;29(5):783-784. PMID: 33647389
MH  - Analgesics/adverse effects/*therapeutic use
MH  - Chronic Pain/*drug therapy/*etiology
MH  - Duloxetine Hydrochloride/adverse effects/*therapeutic use
MH  - Humans
MH  - Low Back Pain/*drug therapy
MH  - Osteoarthritis/*complications
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Chronic low back pain
OT  - Duloxetine
OT  - Meta-analysis
OT  - Osteoarthritis
OT  - Randomized controlled trial
OT  - Systematic review
EDAT- 2020/03/15 06:00
MHDA- 2021/07/20 06:00
CRDT- 2020/03/15 06:00
PHST- 2019/10/15 00:00 [received]
PHST- 2020/02/06 00:00 [revised]
PHST- 2020/03/02 00:00 [accepted]
PHST- 2020/03/15 06:00 [pubmed]
PHST- 2021/07/20 06:00 [medline]
PHST- 2020/03/15 06:00 [entrez]
AID - S1063-4584(20)30915-8 [pii]
AID - 10.1016/j.joca.2020.03.001 [doi]
PST - ppublish
SO  - Osteoarthritis Cartilage. 2020 Jun;28(6):721-734. doi: 
      10.1016/j.joca.2020.03.001. Epub 2020 Mar 10.